Group 1 - The core point of the article is that MicroPort CardioFlow-B (02160.HK) has received a favorable review from the NMPA for its new generation implantable cardioverter-defibrillator (ICD) TILEN/EYLEN, which is expected to be the first domestically approved MRI-safe ICD with independent intellectual property rights [1] - The stock closed at HKD 0.79, up 2.6% with a trading volume of 8.472 million shares and a turnover of HKD 6.6143 million as of February 13, 2026 [1] - The stock has a market capitalization of HKD 4.902 billion and ranks 9th in the medical device II industry [1] Group 2 - MicroPort CardioFlow-B has a Return on Equity (ROE) of 0.24%, which is significantly higher than the industry average of -4.82%, ranking 17th out of 28 [2] - The company's operating revenue is HKD 368 million, compared to the industry average of HKD 1.201 billion, ranking 19th out of 28 [2] - The gross profit margin of MicroPort CardioFlow-B is 70.24%, which is above the industry average of 53.75%, ranking 6th out of 28 [2]